• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

FDA Grants Breakthrough Designation to Admetsys’ Automated Glucose and Continuous Blood Diagnostics System


This will allow the product to arrive in hospitals at a faster pace.

The FDA designated Admetsys Corporation’s automated glucose control and continuous blood diagnostics system as a breakthrough device. This allows Admetsys to accelerate the device’s timeline for being brought to market in the US.

Jeff Valk, Ceo of Admetsys, said in a press release, “The core of the system is its patient-adaptive learning algorithm. Machine intelligence using real-time biosensing data directly drives therapeutic actuation. This represents a new generation of device: fully autonomous clinical robotics."

The device is able to measure a patient’s blood for multiple analytes without any blood loss. It then uses this information to create a model of the patient’s metabolism and make recommendations for precise treatment levels of insulin and dextrose.

Valk continued, “The system unlocks a previously unachievable mode of care. It affects this economically, at scale, while preserving focus for clinicians. Precision automation fundamentally changes the equation."

© 2024 MJH Life Sciences

All rights reserved.